Medulloblastoma: Most Common Malignant Pediatric Brain Tumor — Overview, Diagnosis & Treatment Options | MyMedicPlus

Medulloblastoma is the most common malignant brain tumor in children, comprising approximately 20% of all pediatric central nervous system tumors and roughly 15-20% of intracranial tumors in children under 15 years of age. It arises in the cerebellum (posterior fossa), with a peak incidence at ages 3-9 years. The 2021 WHO CNS Classification defines it as a WHO Grade 4 embryonal tumor and establishes four molecularly distinct subgroups — WNT-activated, SHH-activated, Group 3, and Group 4 — each with distinct biological drivers, prognoses, and emerging subgroup-specific treatment implications. The tumor can spread through cerebrospinal fluid to the leptomeninges and spinal cord (leptomeningeal dissemination), which is present in approximately 30-40% of patients at diagnosis. Adults can also develop medulloblastoma, typically at a median age of 25-35 years, with different subgroup distribution than pediatric patients.

The majority of medulloblastoma cases arise sporadically with no identifiable environmental or familial cause. Hereditary cancer predisposition syndromes account for approximately 15% of cases: Gorlin syndrome (nevoid basal cell carcinoma syndrome, caused by germline PTCH1 mutations) predisposes to the SHH-activated subgroup, typically presenting as desmoplastic medulloblastoma in young children; Turcot syndrome type 2 (germline APC mutations) is associated with the WNT-activated subgroup; Li-Fraumeni syndrome (germline TP53 mutations) occurs in the SHH-activated subgroup and is associated with chromothripsis and extremely poor prognosis; and BRCA2 and PALB2 germline mutations predispose to desmoplastic medulloblastoma in young children. Prior cranial irradiation is a recognized acquired risk factor for secondary medulloblastoma.

Presenting symptoms reflect the combination of cerebellar dysfunction and obstructive hydrocephalus arising from Sylvian aqueduct compression by the posterior fossa mass. Early morning headache that worsens with changes in position (particularly lying down) and the Valsalva maneuver is a classic feature. Projectile vomiting without nausea is characteristic of raised intracranial pressure. Progressive gait ataxia, truncal instability, and limb dysmetria reflect cerebellar hemisphere and vermis involvement. Sixth nerve palsy with diplopia is common due to raised ICP. Papilledema with visual blurring develops from chronic hydrocephalus. Neck stiffness and back pain may indicate leptomeningeal disease. Subtle early manifestations include behavioral changes, irritability, and declining school performance in older children. Symptoms often progress over weeks to a few months before diagnosis.

MRI of the brain with gadolinium contrast reveals a midline posterior fossa mass arising from the cerebellar vermis, with heterogeneous contrast enhancement and diffusion restriction on diffusion-weighted imaging (DWI) — characteristic of high cellular density. Full neuraxis MRI (brain and entire spine) is mandatory to detect leptomeningeal dissemination before surgical debulking alters cerebrospinal fluid cytology. Lumbar puncture for CSF cytology is performed after safe reduction of intracranial pressure. Chang staging system classifies metastatic burden from M0 (no dissemination) to M4 (extraneural metastases). Surgical resection provides tissue for histological classification and comprehensive molecular profiling including subgroup assignment (WNT, SHH, Group 3, Group 4), CTNNB1, PTCH1, TP53, MYC and MYCN amplification status — all critical for risk stratification and trial eligibility.

Treatment follows a three-phase approach based on age and risk stratification. Maximal safe surgical resection (goal: less than 1.5 cm² residual tumor on post-operative MRI within 48 hours) is the first step. For average-risk patients (≥3 years, M0, near-complete resection), standard therapy is 23.4 Gy craniospinal irradiation (CSI) plus a 30 Gy boost to the posterior fossa tumor bed, beginning 4-6 weeks post-operatively, followed by adjuvant chemotherapy with cisplatin, vincristine, and either lomustine or cyclophosphamide. High-risk patients (M+ disease, subtotal resection, or large-cell/anaplastic histology) receive 36 Gy CSI with adjuvant multiagent chemotherapy. WNT-activated patients are candidates for treatment de-intensification in clinical trials. Infants and children under 3 years receive chemotherapy-based approaches to avoid or delay craniospinal irradiation, given its severe late effects on the developing brain. SHH-activated medulloblastoma is a target for vismodegib (hedgehog pathway inhibitor) in post-radiation residual or relapsed adult patients.

No preventive measures exist for sporadic medulloblastoma. For patients with known hereditary syndromes, targeted surveillance can enable earlier detection. Patients with Gorlin syndrome should avoid cranial CT scanning and therapeutic cranial irradiation (which can induce additional basal cell carcinomas and potentially CNS tumors) and undergo annual brain MRI surveillance from early childhood. Li-Fraumeni syndrome and Turcot syndrome carriers require structured cancer surveillance protocols including periodic brain imaging. Genetic counseling is recommended for all pediatric patients with medulloblastoma to identify familial predisposition syndromes, as germline findings have implications for siblings and parents. Avoiding unnecessary ionizing radiation to the head in children reduces the theoretical risk of radiation-induced secondary CNS tumors.

Parents should seek urgent medical evaluation if a child develops persistent morning headaches — especially those severe enough to wake the child from sleep or accompanied by projectile vomiting. Progressive clumsiness, difficulty walking, or unsteady gait that worsens over days to weeks in a child requires immediate neurological assessment. Sudden onset of double vision, crossed eyes, or abnormal eye movements are additional urgent warning signs. Any child or adolescent presenting with signs of raised intracranial pressure — severe headache, repeated vomiting, visual changes, or declining consciousness — needs emergency evaluation with brain MRI. Adults experiencing these symptoms, especially new-onset cerebellar ataxia and headache, should also be promptly evaluated by a neurologist or neurosurgeon.

Five-year survival by molecular subgroup: WNT-activated greater than 90%; SHH-activated approximately 75% (TP53 mutant 40%); Group 3 approximately 45-60%; Group 4 approximately 65-75%. Average-risk patients achieve 5-year OS of 70-80%; high-risk patients 60-65%. Long-term survivorship is complicated by neurocognitive late effects, growth hormone deficiency, hearing loss (cisplatin), and secondary malignancies from radiation. Surveillance MRI continues for at least 5-10 years after treatment. The prognosis for Medulloblastoma: Most Common Malignant Pediatric Brain Tumor varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.